Matt Baker’s Crohn’s Crisis Exposes a Brutal Truth: Modern Medicine Can Control the Disease Without Repairing the Damage
On November 3, 2024, Matt Baker, the creator of the history and education channel UsefulCharts, published a video from his hospital bed. He had spent approximately 10 days unable to eat or drink, with a tube running through his nose into his stomach. Two attempts to reopen a blocked section of his intestine had failed. Surgery was becoming unavoidable.
What made his situation particularly disturbing was that his Crohn’s disease treatment had appeared to be working.
Months of weekly biological injections had reduced his symptoms. His iron levels had stabilized after years of serious problems. He had begun feeling almost normal again.
Then his intestine became obstructed.
Baker described the situation with unsettling simplicity:
“without surgery I'm never going to be able to eat and drink again”
The account deserves defending because it illustrates a medically important distinction that ordinary discussions of Crohn’s disease often obscure: controlling intestinal inflammation is not necessarily the same as restoring the intestine's physical function.
Independent medical research strongly supports that distinction. More importantly, research published since Baker's video demonstrates how much remains uncertain about treating the intestinal narrowing that can develop in Crohn’s disease.
His experience is not proof that his doctors made every correct decision. Nor does it establish that surgery was inevitable from the beginning.
It exposes something more consequential: an important gap between what modern Crohn’s treatments can achieve and what patients sometimes still need.
The Medication Worked. The Intestine Still Failed.
Crohn’s disease is a chronic, immune-mediated inflammatory condition that can affect different parts of the digestive tract.
Modern biological medicines have dramatically changed treatment. By interfering with specific inflammatory pathways, these drugs can reduce symptoms, promote intestinal healing, and help some patients avoid hospitalization and surgery.
Baker experienced those benefits.
After receiving his Crohn’s diagnosis around October 2023, he began weekly injections of a biologic medication. He reported that meaningful improvement took approximately six months.
Eventually, he felt substantially better. His iron levels stabilized.
But improvement in inflammation does not necessarily mean that the intestine has recovered its normal structure.
Crohn’s disease can produce strictures—sections of intestine that become abnormally narrow. These narrowings may contain inflammatory tissue, fibrotic scar tissue, or both.
Inflammation can respond to medication. Established fibrosis is much harder to reverse.
A global expert consensus published in Nature Reviews Gastroenterology & Hepatology in June 2024 reached a consequential conclusion: no medication had demonstrated a specific, proven ability to reverse intestinal fibrosis in Crohn’s disease.
The consensus also found that doctors cannot reliably determine the precise degree of fibrosis using commonly available imaging techniques.
That creates two related problems.
First, a patient may experience substantial relief from inflammation while a dangerous narrowing remains.
Second, determining how much of that narrowing will respond to further medical treatment can be difficult, even with sophisticated imaging. Nature
Baker’s account fits this clinical problem.
His biologic treatment appeared to help control his disease, but a persistent narrowing remained sufficiently serious to cause obstruction.
It would be a mistake to conclude that his medication failed entirely.
A treatment can achieve its intended biological effect without reversing every consequence of the disease.
That distinction is essential to understanding his hospitalization.
The evidence has become more interesting since his video
A 2025 randomized study, known as STRIDENT, examined how intestinal strictures responded to treatment with adalimumab, an anti-inflammatory biological medicine.
Among 77 patients with stricturing Crohn’s disease, 56 experienced a clinical response over 12 months.
Complete resolution of strictures was observed in 29% of evaluable patients using intestinal ultrasound and 22% using MRI.
These results qualify any sweeping claim that medication cannot improve intestinal narrowing.
Some strictures can improve substantially, particularly when inflammation contributes to the obstruction.
But improvement is not guaranteed, and complete resolution occurred in only a minority of the studied patients. The findings cannot be directly applied to Baker because he did not identify his biologic medication or disclose the detailed characteristics of his stricture. PubMed
A further systematic review published in Inflammatory Bowel Diseases in October 2026 exposed the weakness of the broader evidence base.
Researchers screened 22,306 records but ultimately identified only 10 prospective studies meeting their criteria for evaluating medical treatments in stricturing Crohn’s disease.
Those studies primarily examined anti-TNF biological treatments. Evidence was too varied for a reliable pooled analysis, and the review found no qualifying prospective trials specifically assessing small-molecule therapies.
The researchers concluded that better trials and improved imaging methods remain necessary. PubMed
This is the central discovery that strengthens Baker’s account.
Two years after he described his medical crisis, the scientific literature still identified major unanswered questions about treating the particular complication that had put him in hospital.
His experience is not an unusual contradiction of everything medicine knows.
It sits directly inside an area where medicine is still developing reliable answers.
The Camera That Got Stuck Was More Than an Unlucky Accident
One of the most revealing details in Baker's story occurred before his Crohn’s diagnosis.
After years of unexplained anemia, doctors asked him to swallow a capsule containing a miniature camera.
The device was designed to travel through his digestive tract and collect thousands of images.
Instead, it became trapped.
Doctors eventually retrieved the capsule through an endoscopic procedure. Its images helped establish his Crohn’s diagnosis.
Baker said he had been told the chance of the capsule becoming stuck was approximately one in a thousand.
That estimate deserves scrutiny.
A meta-analysis published in Inflammatory Bowel Diseases in 2020 reported capsule-retention rates of approximately 2.35% among patients with suspected Crohn’s disease and 4.63% among those with established disease.
Those figures correspond to roughly one in 43 and one in 22 patients, respectively.
These are pooled estimates from Crohn’s-specific populations, not universal risks for every capsule-endoscopy patient. They cannot establish Baker's individual risk at the time his test was ordered.
Nevertheless, they demonstrate that capsule retention is a recognized and clinically important complication when Crohn’s disease is suspected. PubMed
What makes Baker's experience especially informative is what happened afterward.
The capsule became trapped in a narrowed section of bowel.
Approximately a year later, Baker believed the same narrowing was responsible for the intestinal obstruction that had hospitalized him.
He was careful not to claim certainty about that connection.
His suspicion was medically plausible, but proving it would require access to his imaging, endoscopic findings, and clinical records.
Could the obstruction have been anticipated?
This is the most difficult question raised by the story.
A retained capsule can indicate that a narrowing was already present.
But detecting a stricture is not the same as knowing when it will cause symptoms or whether intervention is immediately necessary.
Guidelines published in 2025 by European inflammatory bowel disease specialists recommend evaluating capsule passage using a dissolvable patency capsule or cross-sectional imaging in patients with established Crohn’s disease.
They also identify prior abdominal surgery and suspected small-bowel disease among the factors that can increase retention risk. DOI
Baker had undergone major intestinal surgery roughly two decades earlier.
That makes the safety considerations surrounding capsule endoscopy particularly relevant.
But there is an important boundary to the investigation.
His video does not establish what imaging doctors performed before the capsule examination, whether they assessed intestinal patency, what warnings they provided, or how they evaluated the narrowing afterward.
Without those details, an accusation of medical negligence would be irresponsible.
The stronger conclusion is that the trapped capsule was a significant clinical finding, not merely an embarrassing technical mishap.
It identified a structural problem that deserved evaluation and monitoring.
The question is not whether doctors should have predicted the future perfectly. It is whether the available methods can reliably identify which intestinal strictures will eventually become dangerous.
The scientific literature indicates that this remains an imperfect process.
Why Two Failed Procedures Do Not Mean the Doctors Made a Mistake
During his hospitalization, Baker underwent two attempts to reopen his narrowed intestine using an inflatable balloon attached to an endoscope.
Neither succeeded.
Surgery was then planned.
To someone unfamiliar with Crohn’s disease, repeated unsuccessful procedures might sound like needless medical experimentation.
The evidence supports a more careful interpretation.
The European Crohn’s and Colitis Organisation's 2024 surgical guidelines recommend endoscopic balloon dilation as an option for selected small-bowel strictures shorter than five centimeters.
The recommendation draws partly on evidence involving 1,463 patients who underwent 3,213 dilation procedures.
That research found that shorter strictures were more likely to be treated successfully without subsequent surgery. Each additional centimeter of stricture length was associated with an 8% increase in the need for surgery.
Multiple dilation attempts may be necessary, and treatment success depends on the individual anatomy and clinical circumstances. OUP Academic
Baker did not disclose his stricture's length, precise location, or detailed appearance.
Consequently, his account cannot establish whether balloon dilation was the optimal initial intervention.
It does establish that the treatment his doctors attempted is a recognized option for suitable Crohn’s-related strictures.
The failure of two attempts does not, by itself, demonstrate poor care.
Nor does it establish that the original treatment decision was correct.
Those are separate questions.
Surgery is not necessarily the defeat of medical treatment
Crohn’s disease can require surgery when inflammation, scarring, or other complications cannot be adequately controlled through medication or endoscopic procedures.
The same 2024 European guidelines recognize intestinal resection and strictureplasty as established surgical options.
Strictureplasty can widen a narrowed section without removing it, potentially preserving valuable bowel length.
That matters because the small intestine performs functions the body cannot simply dispense with.
The surgical guidelines also favor planned procedures over emergency operations when circumstances permit.
A meta-analysis discussed in the guidelines found mortality of approximately 0.6% after elective Crohn’s bowel resections compared with 3.6% after emergency resections.
These figures came from observational studies involving different patient populations. They should not be interpreted as Baker's personal probability of death or proof that postponing surgery is always safer. OUP Academic
The underlying principle remains important.
When possible, correcting nutritional deficiencies and improving a patient's condition before an operation can be valuable.
That leads directly to another striking part of Baker's account.
The Cruel Paradox of Being Too Weak for Surgery Because You Cannot Eat
By the time Baker recorded his video, he had reportedly spent around 10 days without food or drink.
Doctors were providing intravenous fluids to maintain hydration.
But hydration alone does not supply the energy, protein, and essential nutrients required to maintain the body during serious illness.
His medical team faced a difficult situation.
Baker needed surgery to resolve the obstruction.
Yet his prolonged inability to eat had left him nutritionally depleted, making immediate surgery less desirable.
The solution was total parenteral nutrition, or TPN.
Doctors inserted a peripherally inserted central catheter—known as a PICC line—which allowed nutrients to be delivered directly into his bloodstream.
Baker expected to receive this nutrition for at least five days before surgery, followed by further nutritional support during recovery.
This was not an improvised treatment.
Guidelines published by the European Society for Clinical Nutrition and Metabolism in 2023 specifically recognize parenteral nutrition as appropriate when intestinal obstruction prevents adequate oral or tube feeding.
The guidelines generally prefer nutrition through the digestive tract whenever that route is possible, but acknowledge that obstruction can make intravenous nutrition necessary. PubMed
Baker's description therefore aligns with a well-established medical approach.
The precise duration and timing of nutritional support must depend on the patient's condition and the urgency of surgery.
His account does not provide enough information to judge those individual decisions.
But it illustrates why the route back to eating can sometimes begin with nutrition delivered directly into a vein.
There is something almost absurd about being unable to undergo an operation because the condition requiring the operation has prevented you from eating.
Yet the medical reasoning is coherent.
The objective is to make the necessary procedure as safe as circumstances allow.
His Anemia Was a Warning That Something Else Was Wrong
The obstruction was not Baker's first encounter with serious medical complications.
Approximately three years before his video, routine blood tests revealed that his hemoglobin had fallen below 70.
He was told to go immediately to the emergency department and received a blood transfusion.
Doctors initially attributed the problem to insufficient iron in his diet.
Baker began taking iron supplements.
When those failed, he received approximately two dozen intravenous iron infusions.
They did not provide a lasting solution.
One infusion also caused anaphylactic shock, triggering a Code Blue hospital emergency.
Eventually, doctors investigated his digestive tract using increasingly specialized procedures, including the camera capsule that identified Crohn’s disease.
The sequence raises a broader medical question.
What happens when clinicians repeatedly treat a measurable problem without yet identifying its underlying cause?
Iron deficiency and anemia are common complications of inflammatory bowel disease.
Potential mechanisms include intestinal bleeding, impaired absorption, and inflammation-related disruption of iron metabolism.
The American Gastroenterological Association's 2024 clinical guidance recommends intravenous iron in certain circumstances, including when oral iron is ineffective or unlikely to be absorbed.
It also recognizes the need to address the underlying inflammatory bowel disease rather than relying solely on iron replacement. Gastroenterology.org
Baker's history demonstrates why that distinction matters.
His repeated iron treatments did not resolve the problem, but his iron levels reportedly stabilized after Crohn’s treatment became effective.
That sequence is consistent with the underlying intestinal disease contributing to his anemia.
It does not establish the precise mechanism in his case.
Nor does it prove his earlier doctors acted negligently.
His medical records would be necessary to determine what investigations were performed, what competing diagnoses were considered, and whether any opportunities for earlier diagnosis were missed.
The defensible lesson is simpler.
Anemia can be an important warning sign of intestinal disease, even when digestive symptoms do not immediately reveal the underlying problem.
Twenty Years With an Ostomy: What Baker Understands That Outsiders Often Miss
Baker's video contains another revelation that deserves attention.
At 29, he underwent surgery to remove his colon after developing severe ulcerative colitis.
For approximately 20 years afterward, he lived with an ileostomy.
Waste leaves his body through a surgically created opening in his abdomen and collects in an external bag.
Many people unfamiliar with ostomies might assume that such an operation necessarily produces a diminished life.
Baker described a different experience.
“it's allowed me to live um a much better life than before”
That observation is supported by a substantial body of patient-outcome research.
A study of 351 people who underwent colectomy for ulcerative colitis, involving patients from Canada, Australia, and the United Kingdom, found that 84% reported improved quality of life after surgery.
The improvement was not without complications.
The same study found that 81% experienced difficulties in at least one area, including body image, diet, work, psychological health, or sexual function. PubMed
Those findings make Baker's account more credible, not less.
An ostomy can create practical and psychological challenges while still representing an enormous improvement over severe, uncontrolled intestinal disease.
There is no contradiction.
The comparison that matters is not between an ostomy and an imaginary life without illness.
It is between the circumstances a patient actually faced before surgery and the life that became possible afterward.
But his explanation of ulcerative colitis needs one qualification
Baker describes removal of the colon as essentially curing ulcerative colitis.
That is broadly consistent with the disease's confinement to the large intestine, although the full surgical treatment and its consequences are more complicated.
The Crohn’s & Colitis Foundation explains that removing the colon and rectum can eliminate the diseased intestinal tissue in ulcerative colitis, but patients may still experience surgical complications or other health problems.
Crohn’s disease is fundamentally different because inflammation can develop elsewhere in the digestive tract, including the remaining small intestine. Crohn’s & Colitis Foundation
Baker's later Crohn’s diagnosis does not, by itself, establish whether he developed a separate condition or whether the original disease classification should be reconsidered.
That question would require historical pathology and medical records.
What can be defended is his larger point: an ostomy enabled him to live much better for approximately two decades, yet it did not make him immune to subsequent intestinal disease.
His willingness to explain the arrangement publicly also challenges an enduring stigma surrounding bowel surgery.
Rather than treating the ostomy as an unspeakable personal embarrassment, he presented it as an ordinary feature of his daily life.
That is not a medical breakthrough.
It is a useful correction to how such surgery is often imagined.
The Hospitalization Had Another Patient Who Wasn't in the Hospital
One of the most consequential details in Baker's account had little to do with his own digestive system.
His wife is disabled.
Because Baker ordinarily works from home, he is available throughout the day to assist her.
His hospitalization disrupted that arrangement.
She had to rely on other people and paid helpers.
Baker explained that this assistance could not fully replace having her partner at home.
This is an important distinction between the medical consequences of hospitalization and its wider household consequences.
Baker was not only a patient temporarily removed from his work.
He was also a caregiver temporarily removed from someone who relied on him.
His medical crisis therefore created a second practical crisis within the household.
The situation complicates the usual assumption that hospitalization affects primarily the person occupying the hospital bed.
It also helps explain why Baker could be financially secure while still facing serious problems.
Money could purchase some assistance.
It could not entirely replace his presence.
His account is particularly credible on this point because he did not exaggerate the financial consequences.
Instead, he explicitly told viewers that he and his wife were doing well financially, partly because of the success of UsefulCharts.
He discouraged personal donations and proposed directing contributions toward Crohn's-related charitable causes.
That statement does not independently verify his finances or charitable fundraising results.
But it establishes that his public appeal was not presented as a request to fund his own recovery.
What Baker Got Right—and Where the Evidence Stops
A serious defense should not confuse a moving story with independently verified medical evidence.
Baker's account is firsthand testimony.
It provides information about his reported diagnoses, symptoms, treatments, and personal circumstances.
It does not provide laboratory records, scans, operative reports, or access to his doctors.
Consequently, independent research can establish whether the medical circumstances he describes are plausible and consistent with recognized practice.
It cannot confirm every event or determine whether his individual treatment was optimal.
Several qualifications matter.
First, biologic medicines differ considerably. Baker's description of increased infection risk is broadly reasonable, but the degree of immunosuppression varies by treatment, and not every biologic carries identical risks.
A 2026 European clinical guideline emphasizes that infection risk depends on the medication, accompanying treatments, and individual patient characteristics. OUP Academic
Second, intestinal strictures do not always require surgery. The STRIDENT research demonstrates that some patients experience meaningful improvements with medication, including complete resolution of narrowing in selected cases.
Third, Baker's trapped camera capsule was an important warning sign, but his account does not establish that the subsequent obstruction could definitely have been prevented.
Fourth, surgery itself does not cure Crohn’s disease. It can remove or repair a troublesome segment, but inflammation and complications may recur elsewhere.
These qualifications narrow the defense without undermining its central finding.
Baker was not making a scientific claim that every patient with Crohn’s disease will eventually require surgery.
He was explaining how his own apparent recovery had been interrupted by a persistent structural complication.
The available medical evidence makes that experience entirely credible.
What happened afterward?
Baker recorded his video on the eve of the November 5, 2024, American presidential election.
He hoped to recover by December and resume his usual work.
He also explained that Part Four of his evolutionary history series had already been completed apart from animation.
That installment, Evolutionary Tree of Life: Plants & Fungi, was subsequently published on November 29, 2024, with Baker credited for the chart and narration. YouTube
His channel continued publishing educational material in subsequent years.
That confirms that his announced creative work continued.
It does not independently establish the result of his planned operation, the duration of his recovery, or his current medical condition.
Those details should not be invented to give his story a more satisfying ending.
The Verdict: The Real Failure Would Be Mistaking Symptom Control for a Cure
Matt Baker deserves a defense built on evidence, not sympathy alone.
His experience illustrates how Crohn’s disease can remain structurally dangerous even after medication has improved inflammation and symptoms.
The retained camera capsule suggests that a narrowing had already been present. The later obstruction demonstrates the potential consequences of such a narrowing, although the available information does not prove that both incidents involved the identical lesion.
The unsuccessful balloon dilations and subsequent preparation for surgery are consistent with recognized approaches to complicated Crohn’s disease.
His prolonged dependence on intravenous nutrition demonstrates how intestinal obstruction can create a difficult cycle of nutritional depletion and medical risk.
And his account of living with an ostomy challenges the assumption that major bowel surgery necessarily means surrendering a fulfilling life.
The strongest objection is that an individual patient's story cannot prove a general medical conclusion.
Correct.
But Baker's narrative does not need to carry that burden.
Clinical research published before and after his video independently establishes the reality of stricturing Crohn’s disease, the limitations of current treatments, and the continued need for endoscopic and surgical intervention.
The deeper problem is not that modern biological medicines are ineffective.
They can be extraordinarily valuable.
It is that reducing inflammation, relieving symptoms, reversing fibrosis, and preventing future obstruction remain different medical achievements.
Patients may experience one without achieving all the others.
That distinction matters for treatment expectations, monitoring decisions, research priorities, and the way chronic illness is understood.
Baker's video makes the problem painfully concrete.
A person can feel better. Their blood tests can improve. Their medication can be working.
And somewhere inside their body, an intestinal passage can still be closing.
That is the uncomfortable truth his experience helps explain.
And it is worth defending.
References
Original work
1. Matt Baker — My Crohn's Journey So Far. UsefulCharts, YouTube, November 3, 2024.
Watch the original video
Role: Original firsthand account. Establishes Baker's reported medical history, hospitalization, treatments, personal circumstances, and statements. His individual medical records were not independently reviewed.
Supporting scientific evidence
2. Bettenworth et al. — A Global Consensus on the Definitions, Diagnosis and Management of Fibrostenosing Small Bowel Crohn's Disease in Clinical Practice. Nature Reviews Gastroenterology & Hepatology, June 2024.
Read the consensus
Evidence: Establishes the limitations of diagnosing and treating intestinal fibrosis, including the absence of proven, specifically anti-fibrotic medication.
3. Adamina et al. — ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. Journal of Crohn's and Colitis, October 2024.
Read the guidelines
Evidence: Supports the discussion of balloon dilation, planned surgery, surgical options, and preoperative preparation.
4. Lovett et al. — Crohn's Disease Stricture Response to Treatment Assessed with Magnetic Resonance Imaging and Intestinal Ultrasound: STRIDENT Randomized Trial. Inflammatory Bowel Diseases, 2025.
Read the study
Evidence: Demonstrates that some intestinal strictures can improve or resolve with biological therapy, limiting claims that narrowing is always irreversible.
5. Merola et al. — The Missing Evidence: Stricturing Crohn's Disease in Clinical Trials, a Systematic Review. Inflammatory Bowel Diseases, October 2026.
Read the systematic review
Evidence: Identifies major gaps in prospective research into stricturing Crohn’s disease and the need for better treatment studies.
6. Pasha et al. — Capsule Retention in Crohn's Disease: A Meta-analysis. Inflammatory Bowel Diseases, January 2020.
Read the meta-analysis
Evidence: Provides pooled capsule-retention rates for suspected and established Crohn’s disease. These population estimates cannot establish Baker's individual risk.
7. ECCO–ESGAR–ESP–IBUS — Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 2. Journal of Crohn's and Colitis, 2025.
Read the diagnostic guidelines
Evidence: Explains capsule-endoscopy precautions, intestinal patency testing, and recognized retention risks.
8. Bischoff et al. — ESPEN Guideline on Clinical Nutrition in Inflammatory Bowel Disease. Clinical Nutrition, March 2023.
Read the nutrition guidelines
Evidence: Establishes accepted indications for intravenous nutritional support when intestinal obstruction prevents adequate feeding.
9. DeLoughery et al. — Management of Iron Deficiency Anemia. American Gastroenterological Association, June 2024.
Read the clinical guidance
Evidence: Explains appropriate use of oral and intravenous iron therapy, including situations involving inflammatory bowel disease.
10. Long-term Outcomes of Colectomy Surgery Among Patients with Ulcerative Colitis. SpringerPlus, 2015.
Read the study
Evidence: Reports improved quality of life among many colectomy patients while documenting continuing physical and psychological difficulties.
11. Surgery for Ulcerative Colitis. Crohn’s & Colitis Foundation, patient education resource.
Read the surgical overview
Evidence: Explains the relationship between colectomy, ulcerative colitis, ostomy formation, and potential postoperative complications.
12. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2026.
Read the infection guidelines
Evidence: Qualifies Baker's discussion of immunosuppression by distinguishing the infection risks of different treatments and patient circumstances.
Subsequent development
13. UsefulCharts — Evolutionary Tree of Life: Episode 4 — Plants & Fungi. YouTube, November 29, 2024.
Watch the episode
Evidence: Independently confirms publication of the educational project Baker said was almost ready during his hospitalization; it does not verify his surgical outcome or subsequent health.